Promising new clinical data about novel Lp(a) lowering agents were presented at the American Heart Association Scientific Sessions 2024 (November 16-18, Chicago, USA). Further presentations included studies on the impact of Lp(a) testing in clinical practice and its potential for identifying vulnerable individuals with coronary artery disease, and research into a possible role for lipid lowering treatment in patients with aortic valve calcification.
Reports by Jenny Bryan
Read the reports:
